PXMD | PaxMedica, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1050 - 0.1050
52 Week Range	0.0550 - 1.1900
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	1,893
Average Volume	77,320
Shares Outstanding	10,879,200
Market Cap	1,142,316
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-08-26

Valuation
Profitability
Growth
Health
P/E Ratio	-0.04
Forward P/E Ratio	N/A
EPS	-2.77
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	USA
Website	PXMD

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.

PXMD's peers: ADTX, COCP, CELZ, ENSC, GOVX, KPRX, KTTA, NRBO, NRSN, QNRX, REVB, SABS, SPRC, TCBP, TENX, OKYO, VRAX, PEGY, CMND

*Chart delayed

Analyzing fundamentals for PXMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PXMD Fundamentals page.

Watching at PXMD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PXMD Technicals page.